Early, Precise and Non-Invasive Prostate Cancer Detection

Pre-FDA approved, Prostac™ is a patented, straightforward and non-invasive molecular-based blood test for the early, precise detection** of prostate cancer. 

 ​
Prostac™ can replace the Prostate-Specific Antigen (PSA) test for men who want a single test that will tell them with confidence whether they have or do not have prostate cancer.  These men can include those who are 'at risk' for prostate cancer based on a family history, an African ancestry, or working in jobs or industries which have shown to have higher rates of prostate cancer.      

​

Optionally, men with higher PSA scores can use the Prostac™ to verify a prostate cancer diagnosis. Men testing negative with Prostac™ would then avoid the expensive, intrusive and often harmful screening tests, and even more expensive and potentially life-damaging overtreatments. 

Prostac™ takes away the worry and stress of an uncertain prostate cancer diagnosis and gives men the peace of mind and the confidence to take control of their personal health and well-being.   

**  Note: Prostac™ is a better predictor of prostate cancer than PSA with better specificity, sensitivity and accuracy.